Liverpool Chirochem

Liverpool ChiroChem (LCC) specializes in the design, synthesis, and supply of small organic molecules, particularly chiral N-heterocycles, for research and development in the pharmaceutical industry. Operating in the drug discovery market, LCC serves pharmaceutical companies, biotech firms, and academic institutions. The company leverages advanced synthetic technologies, including catalytic enantioselective reduction, asymmetric hydrogenation, and catalytic cross-couplings, to create high-purity compounds with confirmed stereochemistry. LCC's business model revolves around providing these specialized compounds as building blocks, fragments, and screening compounds, facilitating the drug development process from hit identification to lead optimization. Revenue is generated through the sale of these compounds and custom synthesis services. Additionally, LCC offers a cloud-based platform featuring a virtual library of 1 billion drug-like compounds, enhancing the efficiency of molecular design and drug discovery.

Keywords: chiral N-heterocycles, drug discovery, pharmaceutical R&D, asymmetric hydrogenation, catalytic cross-couplings, virtual library, molecular design, custom synthesis, high-purity compounds, lead optimization.